{"title":"降钙素基因相关肽拮抗剂在宿醉头痛治疗中的潜在作用。","authors":"Sameh M Hakim","doi":"10.1097/ACO.0000000000001553","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to provide an update on the mechanisms of alcohol-induced headache (AIH) and the potential role of calcitonin gene-related peptide (CGRP) antagonists in the management of AIH.</p><p><strong>Recent findings: </strong>AIH is currently believed to be a state of neurogenic inflammation involving the trigeminovascular nociceptive system. There is evidence that alcohol and its metabolites trigger an intricate cascade of reactions and responses in which the mediators of oxidative stress and CGRP play a pivotal role. Evidence from animal models of AIH indicates that CGRP antagonists could be effective in counteracting the manifestations of AIH. Although CGRP antagonists have been approved for the prevention and treatment of migraine headaches, these agents have not been studied within the clinical context of AIH in humans to date. Moving to phase 1 clinical trials may therefore be warranted to elucidate the potential for using these medications in this clinical setting.</p><p><strong>Summary: </strong>CGRP antagonists could be a promising option for the treatment and prevention of AIHs, but clinical evidence is still lacking. Embarking on phase 1 clinical trials exploring the efficacy and safety of CGRP antagonists for AIH may now be expected to be the upcoming step.</p>","PeriodicalId":520600,"journal":{"name":"Current opinion in anaesthesiology","volume":" ","pages":"669-673"},"PeriodicalIF":2.1000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The potential role of calcitonin gene-related peptide antagonists for the management of hangover headaches.\",\"authors\":\"Sameh M Hakim\",\"doi\":\"10.1097/ACO.0000000000001553\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>The purpose of this review is to provide an update on the mechanisms of alcohol-induced headache (AIH) and the potential role of calcitonin gene-related peptide (CGRP) antagonists in the management of AIH.</p><p><strong>Recent findings: </strong>AIH is currently believed to be a state of neurogenic inflammation involving the trigeminovascular nociceptive system. There is evidence that alcohol and its metabolites trigger an intricate cascade of reactions and responses in which the mediators of oxidative stress and CGRP play a pivotal role. Evidence from animal models of AIH indicates that CGRP antagonists could be effective in counteracting the manifestations of AIH. Although CGRP antagonists have been approved for the prevention and treatment of migraine headaches, these agents have not been studied within the clinical context of AIH in humans to date. Moving to phase 1 clinical trials may therefore be warranted to elucidate the potential for using these medications in this clinical setting.</p><p><strong>Summary: </strong>CGRP antagonists could be a promising option for the treatment and prevention of AIHs, but clinical evidence is still lacking. Embarking on phase 1 clinical trials exploring the efficacy and safety of CGRP antagonists for AIH may now be expected to be the upcoming step.</p>\",\"PeriodicalId\":520600,\"journal\":{\"name\":\"Current opinion in anaesthesiology\",\"volume\":\" \",\"pages\":\"669-673\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in anaesthesiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ACO.0000000000001553\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in anaesthesiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ACO.0000000000001553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
The potential role of calcitonin gene-related peptide antagonists for the management of hangover headaches.
Purpose of review: The purpose of this review is to provide an update on the mechanisms of alcohol-induced headache (AIH) and the potential role of calcitonin gene-related peptide (CGRP) antagonists in the management of AIH.
Recent findings: AIH is currently believed to be a state of neurogenic inflammation involving the trigeminovascular nociceptive system. There is evidence that alcohol and its metabolites trigger an intricate cascade of reactions and responses in which the mediators of oxidative stress and CGRP play a pivotal role. Evidence from animal models of AIH indicates that CGRP antagonists could be effective in counteracting the manifestations of AIH. Although CGRP antagonists have been approved for the prevention and treatment of migraine headaches, these agents have not been studied within the clinical context of AIH in humans to date. Moving to phase 1 clinical trials may therefore be warranted to elucidate the potential for using these medications in this clinical setting.
Summary: CGRP antagonists could be a promising option for the treatment and prevention of AIHs, but clinical evidence is still lacking. Embarking on phase 1 clinical trials exploring the efficacy and safety of CGRP antagonists for AIH may now be expected to be the upcoming step.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
